PubVisualPubVisual Book a Demo
Resources Blog About Contact Book a 30-Minute Demo →

A Beginner’s Guide to Pharma Market Segmentation

Segmentation gets a physician the right publication. It rarely gets her the right moment inside it.

The short version
  • Segmentation decides who receives what: the endocrinologist gets the diabetes data, the specialist gets the deeper version. It answers who, not what happens once she opens it.
  • Two community cardiologists on the same distribution list can still want two different things from the very same publication.
  • One approved publication becomes a set of routes: mechanism, outcomes, patient fit. She steers, and every route still traces back to one approved core.

Segmentation gets a physician the right publication. It rarely gets her the right moment inside it. Here's what we found, and what it means for how you build your next story.

01What segmentation actually does

Segmentation decides who receives what: the endocrinologist gets the diabetes data, the specialist gets the deeper version. Here's the part that doesn’t get talked about enough: segmentation answers who should get this. It doesn’t answer what happens once she opens it.

Same finding, two shapesStatic page
The publication as published
The same finding, designed
One finding

A Beginner’s Guide to Pharma Market Segmentation, told as a story a physician can finish.

The physician readerstill scanning the table…
0:38time to the point
Fig. 01The same approved finding, shown as a static page and as a designed story.

02Where the model runs out of road

Two community cardiologists on the same distribution list can still want two different things. Segmentation put the same document in front of both, because segmentation stops at specialty.

“Segmentation answers who should get this. It doesn't answer what happens once she opens it.”

03A publication that keeps segmenting after it's opened

One approved publication becomes a set of routes: mechanism, outcomes, patient fit. She steers. We don’t track what she clicks. Every route she could choose still traces back to one approved core, so one MLR review covers all of it.

04Where this fits in your current process

Bring us the publication and the therapeutic-area context you already have, we handle the mapping and the build. Nothing about your targeting changes.

The Impact Gap ReportFree · request access
Request the report →
PubVisual Smart Pathways

The truest segmentation is the one physicians do themselves.

Slides can describe segments. Smart Pathways lets each physician pick the line that fits them, built entirely from content that already cleared review. Tap a face and follow their line.

Mechanism Subgroup biology Primary endpoint Comparator data Who benefits Dosing in practice
Dr. Marchetti follows the mechanism line.
Self-running · tap a line or a face to follow it

Segmentation you do not have to guess at: each physician picks their own line.

  • Physicians choose specialty, interest and depth. The choosing is the segmentation.
  • No new claims get created. The branches recombine what was already approved.
  • You publish once. Each reader takes it their own way, in the field or in the inbox.
Written by
The PubVisual Team
Editorial · PubVisual

We build the science communication our own field teams would want to use, then hand it to yours. This post came out of that same process.

More from the blog →
The Science of Engagement

Let her steer, from the same approved core

Smart Pathways turns one approved publication into a route for every physician who opens it, not just every segment you targeted.

Questions

Frequently asked questions

Segmentation answers who should get this. It doesn't answer what happens once she opens it. Two community cardiologists on the same distribution list can still want two different things from the very same publication.

No. Every route she could choose traces back to one approved core, so one review covers all of it.

No. Bring the publication and the therapeutic-area context you already have, and we handle the mapping and the build. Nothing about your targeting changes.